# TrojanBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trojanbio

- Industry: Biotechnology
- Headquarters: Ness Ziona, Israel
- Website: www.trojan-bio.com/
- Latest round: Seed (Dec 1, 2023)
- Investors on record: 1

## About

Founded in 2021 and based in Ness Ziona, Israel, TrojanBio Ltd. operates as a pre-clinical immunotherapy company that engages in developing therapeutic antibodies for the treatment of cancers. Anat Burkovitz (CEO), Amir Aharoni, and Noam Diamant are the co-founders of the company. In January 2022, TrojanBio Ltd. raised pre-seed funding from NFX.

The company offers a Trojan platform, which is an AI-driven antibody solution that presents an approach to combating a wide spectrum of cancer types by harnessing the power of viral-specific immunity. The firm’s product includes a Trojan bi-specific antibody that comprises two essential modules: a cancer-targeting module and a viral immunity activation module. This combination allows the antibody to target cancer cells and label them as virally infected cells, activating the anti-viral immunity mechanism to combat cancer. TrojanBio’s pipeline includes TRJ-E84, an anti-EGFR-CMV peptide Trojan antibody for colon cancer treatment; TRJ-T75, designed to combat triple-negative breast cancer (TNBC) by targeting Trop2-CMV peptides; and TRJ-103, which hold the potential to further expand the company's therapeutic offerings.

## Funding rounds

- Seed, Dec 1, 2023 — Peregrine Ventures
- Seed, Apr 1, 2023 — Peregrine Ventures

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Seed